Tag: psychedelics
MindMed Announces 2021 Q1 Financial Results; Cash Balance of $160m USD
Mind Medicine (MindMed) Inc. (“MindMed” or the “Company”) (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), a…
NYU Langone receives $10 million dollar donation to help found Center for Psychedelic Medicine
There has never been a time when interest in psychedelic medicines and their benefit has…
MindMed streamlines leadership with further emphasis on integrating psychedelic drug development with digital medicines and therapeutics
J.R. Rahn to become sole CEO; Perry Dellelce to become Chair; Stephen Hurst retires as executive but remains on…
The world’s first psychedelic ETF has landed; boom to follow
At a time when the trading world is discussing Gamestop and the “dangers” of outsider…
Recent Comments